IE
PCVX icon

Israel Englander’s Vaxcyte PCVX Stock Holding History

Israel Englander’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-51,000
Closed -$1.93M – 6213
2025
Q1 		$1.93M Buy
+51,000
New +$4.08M ﹤0.01% 3818

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Israel Englander's PCVX Position: Q2 2026 in Review

Israel Englander reduced its Vaxcyte (PCVX) stake by 53% in Q2 2026, selling an estimated $8.53M and leaving 136,625 shares worth $7.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2541.

Israel Englander first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $60.6M in Q2 2023. 330 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Israel Englander held 136,625 shares of Vaxcyte worth $7.94M as of Q2 2026.
  • Israel Englander sold 157,070 Vaxcyte shares in Q2 2026, an estimated $8.53M.
  • Vaxcyte made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2541 holding.
  • Israel Englander first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • Israel Englander's Vaxcyte position peaked at $60.6M in Q2 2023.
  • 330 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.